Bavarian Nordic reports promising results for RSV vaccine in phase II trial
On Wednesday morning, Bavarian Nordic announced positive results for the company’s RSV vaccine candidate. According to the biotech company, the candidate has shown an efficacy rate of up to 79 percent in the reduction of symptomatic RSV infections in a phase II trial.
BY CHRISTOFFER DUE KARLSSON, TRANSLATED BY DANIEL INGEMANN KROIER PEDERSEN
The positive news just keeps on coming for Bavarian Nordic.
The vaccine company is reporting positive results for its vaccine candidate against respiratory syncytial virus, also known as RSV.
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.